Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma

B‐cell activating factor (BAFF) promotes the survival and adhesion of multiple myeloma (MM) cells. Tabalumab (LY2127399) is an anti‐BAFF monoclonal antibody. This phase 1, multicenter, open‐label, nonrandomized, dose‐escalation study evaluated the safety, tolerability, pharmacokinetics, pharmacodyna...

Descripción completa

Detalles Bibliográficos
Autores principales: Iida, Shinsuke, Ogiya, Daisuke, Abe, Yasunobu, Taniwaki, Masafumi, Asou, Hiroya, Maeda, Kaijiro, Uenaka, Kazunori, Nagaoka, Soshi, Ishiki, Tsuyoshi, Conti, Ilaria, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021044/
https://www.ncbi.nlm.nih.gov/pubmed/27350068
http://dx.doi.org/10.1111/cas.13000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021044/
https://www.ncbi.nlm.nih.gov/pubmed/27350068
http://dx.doi.org/10.1111/cas.13000

Ejemplares similares